Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome

Hans Uwe Simon; Sabine Plötz; Dagmar Simon; Ulrike Seitzer; Lasse R. Braathen; Günter Menz; Alex Straumann; Reinhard Dummer; Francesca Levi-Schaffer

doi:10.1002/eji.200323727

Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome

Hans Uwe Simon^*, Sabine Plötz, Dagmar Simon, Ulrike Seitzer, Lasse R. Braathen, Günter Menz, Alex Straumann, Reinhard Dummer, Francesca Levi-Schaffer

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Patients with hypereosinophilia frequently suffer from eosinophil-mediated damages of the heart, lungs, skin, and other organs, while some do not. The reason(s) for this difference is not known. We observed that eosinophils from most patients with hypereosinophilia express the α-chain of the IL-2 receptor (CD25), and that IL-2 enhances platelet-activating factor-stimulated release of eosinophil cationic protein from CD25-expressing but not from CD25-negative eosinophils. Such a "priming" effect has previously been described for eosinophil hematopoietins. These data suggest that patients with increased eosinophil surface CD25 expression are at higher risk of eosinophil degranulation and subsequent tissue damage when IL-2 is present at inflammatory sites.

Original language	English
Pages (from-to)	834-839
Number of pages	6
Journal	European Journal of Immunology
Volume	33
Issue number	4
DOIs	https://doi.org/10.1002/eji.200323727
State	Published - 1 Apr 2003

Keywords

Degranulation
Eosinophil
Hypereosinophilia
IL-2
Priming

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/eji.200323727

Cite this

@article{7013e4c69afb494d9730af0a86c64059,

title = "Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome",

abstract = "Patients with hypereosinophilia frequently suffer from eosinophil-mediated damages of the heart, lungs, skin, and other organs, while some do not. The reason(s) for this difference is not known. We observed that eosinophils from most patients with hypereosinophilia express the α-chain of the IL-2 receptor (CD25), and that IL-2 enhances platelet-activating factor-stimulated release of eosinophil cationic protein from CD25-expressing but not from CD25-negative eosinophils. Such a {"}priming{"} effect has previously been described for eosinophil hematopoietins. These data suggest that patients with increased eosinophil surface CD25 expression are at higher risk of eosinophil degranulation and subsequent tissue damage when IL-2 is present at inflammatory sites.",

keywords = "Degranulation, Eosinophil, Hypereosinophilia, IL-2, Priming",

author = "Simon, {Hans Uwe} and Sabine Pl{\"o}tz and Dagmar Simon and Ulrike Seitzer and Braathen, {Lasse R.} and G{\"u}nter Menz and Alex Straumann and Reinhard Dummer and Francesca Levi-Schaffer",

year = "2003",

month = apr,

day = "1",

doi = "10.1002/eji.200323727",

language = "אנגלית",

volume = "33",

pages = "834--839",

journal = "European Journal of Immunology",

issn = "0014-2980",

publisher = "Wiley-VCH Verlag",

number = "4",

}

TY - JOUR

T1 - Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome

AU - Simon, Hans Uwe

AU - Plötz, Sabine

AU - Simon, Dagmar

AU - Seitzer, Ulrike

AU - Braathen, Lasse R.

AU - Menz, Günter

AU - Straumann, Alex

AU - Dummer, Reinhard

AU - Levi-Schaffer, Francesca

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Patients with hypereosinophilia frequently suffer from eosinophil-mediated damages of the heart, lungs, skin, and other organs, while some do not. The reason(s) for this difference is not known. We observed that eosinophils from most patients with hypereosinophilia express the α-chain of the IL-2 receptor (CD25), and that IL-2 enhances platelet-activating factor-stimulated release of eosinophil cationic protein from CD25-expressing but not from CD25-negative eosinophils. Such a "priming" effect has previously been described for eosinophil hematopoietins. These data suggest that patients with increased eosinophil surface CD25 expression are at higher risk of eosinophil degranulation and subsequent tissue damage when IL-2 is present at inflammatory sites.

AB - Patients with hypereosinophilia frequently suffer from eosinophil-mediated damages of the heart, lungs, skin, and other organs, while some do not. The reason(s) for this difference is not known. We observed that eosinophils from most patients with hypereosinophilia express the α-chain of the IL-2 receptor (CD25), and that IL-2 enhances platelet-activating factor-stimulated release of eosinophil cationic protein from CD25-expressing but not from CD25-negative eosinophils. Such a "priming" effect has previously been described for eosinophil hematopoietins. These data suggest that patients with increased eosinophil surface CD25 expression are at higher risk of eosinophil degranulation and subsequent tissue damage when IL-2 is present at inflammatory sites.

KW - Degranulation

KW - Eosinophil

KW - Hypereosinophilia

KW - IL-2

KW - Priming

UR - http://www.scopus.com/inward/record.url?scp=0037731340&partnerID=8YFLogxK

U2 - 10.1002/eji.200323727

DO - 10.1002/eji.200323727

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 12672048

AN - SCOPUS:0037731340

SN - 0014-2980

VL - 33

SP - 834

EP - 839

JO - European Journal of Immunology

JF - European Journal of Immunology

IS - 4

ER -

Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this